$4 million non dilutive and potentially $6.6 million when the...

$4 million non dilutive and potentially $6.6 million when the July meeting approves the tranche 2 of the last CR.

Market cap of sub $8 million. It's not a bad effort.

I was there in the beginning, Steini. Half the shares were in escow for the first year. But that was then when people threw money at biotechs, and risk was accepted. Totally different environment now. Again, look at how OPT organised its finance and the repercussions of that to see what the real world is like. CHM has luckily been able to avoid that, even when raises aren't supported by shareholders.

CHM is in the best position it has been in for a very long time. Potentially, a company making ouvot before end of year if datavis good enough to on board a partner.

Your trying to draw parallels to another company doesn't take into account CHM having to sideline its then lead drug and start the pipeline with another. I have mentioned the cost of this many times. And that's where the dilution has stemmed from. Read the end of year reports and 4Cs, they tell the story.